230 related articles for article (PubMed ID: 23915912)
1. Regulation of SIRT2 levels for human non-small cell lung cancer therapy.
Li Z; Xie QR; Chen Z; Lu S; Xia W
Lung Cancer; 2013 Oct; 82(1):9-15. PubMed ID: 23915912
[TBL] [Abstract][Full Text] [Related]
2. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.
Grbesa I; Pajares MJ; Martínez-Terroba E; Agorreta J; Mikecin AM; Larráyoz M; Idoate MA; Gall-Troselj K; Pio R; Montuenga LM
PLoS One; 2015; 10(4):e0124670. PubMed ID: 25915617
[TBL] [Abstract][Full Text] [Related]
3. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
Li Z; Huang J; Yuan H; Chen Z; Luo Q; Lu S
Oncotarget; 2016 Apr; 7(14):18927-39. PubMed ID: 26942878
[TBL] [Abstract][Full Text] [Related]
4. SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Xu W; Jiang K; Shen M; Qian Y; Peng Y
Biol Chem; 2015 Aug; 396(8):929-36. PubMed ID: 25719312
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
6. SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.
Luo J; Bao YC; Ji XX; Chen B; Deng QF; Zhou SW
Biochem Biophys Res Commun; 2017 Feb; 483(2):880-884. PubMed ID: 28073696
[TBL] [Abstract][Full Text] [Related]
7. Depletion of end-binding protein 1 (EB1) promotes apoptosis of human non-small-cell lung cancer cells via reactive oxygen species and Bax-mediated mitochondrial dysfunction.
Kim MJ; Yun HS; Hong EH; Lee SJ; Baek JH; Lee CW; Yim JH; Kim JS; Park JK; Um HD; Hwang SG
Cancer Lett; 2013 Oct; 339(1):15-24. PubMed ID: 23900080
[TBL] [Abstract][Full Text] [Related]
8. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
9. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
10. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-Cell Chronic Lymphocytic Leukemia (CLL).
Bhalla S; Gordon LI
Cancer Biol Ther; 2016; 17(3):300-9. PubMed ID: 26794150
[TBL] [Abstract][Full Text] [Related]
12. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
13. Sirt2 suppresses glioma cell growth through targeting NF-κB-miR-21 axis.
Li Y; Dai D; Lu Q; Fei M; Li M; Wu X
Biochem Biophys Res Commun; 2013 Nov; 441(3):661-7. PubMed ID: 24161395
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target.
Fan T; Li R; Todd NW; Qiu Q; Fang HB; Wang H; Shen J; Zhao RY; Caraway NP; Katz RL; Stass SA; Jiang F
Cancer Res; 2007 Aug; 67(16):7901-6. PubMed ID: 17699796
[TBL] [Abstract][Full Text] [Related]
15. SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.
Shin DH; Choi YJ; Park JW
Cancer Res; 2014 Jan; 74(1):298-308. PubMed ID: 24240701
[TBL] [Abstract][Full Text] [Related]
16. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.
Zhang W; Wan M; Ma L; Liu X; He J
Cell Biol Int; 2013 Jan; 37(1):47-53. PubMed ID: 23319321
[TBL] [Abstract][Full Text] [Related]
18. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis.
Li Y; Matsumori H; Nakayama Y; Osaki M; Kojima H; Kurimasa A; Ito H; Mori S; Katoh M; Oshimura M; Inoue T
Genes Cells; 2011 Jan; 16(1):34-45. PubMed ID: 21059157
[TBL] [Abstract][Full Text] [Related]
19. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
20. miR‑150 promotes the proliferation and migration of non‑small cell lung cancer cells by regulating the SIRT2/JMJD2A signaling pathway.
Jiang K; Shen M; Chen Y; Xu W
Oncol Rep; 2018 Aug; 40(2):943-951. PubMed ID: 29901178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
